메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Sakai Clinic 62 Founder & Medical Director Mari Sakai Holds Dialo…

TOKYO, Jan. 20, 2026 -- Sakai Clinic 62 (Location: Shibuya-ku, Tokyo; Founder & Medical Director: Mari Sakai) announces that Dr. Mari Sakai held a dialogue with Mr. Peter Nobel, Chairman of the Nobel Sustainability Trust (NST), to discuss the international promotion of sustainability within the medical field. The Nobel Sustainability Trust (NST) is an international foundation established by members of the Nobel family, dedicated to advancing sustainability by bridging scientific research and real-world implementation. During this dialogue, insights from regenerative medicin
- 김갑성 기자
- 2026-01-20 00:00
FDA Grants Regenerative Medicine Advanced Therapy (RMAT…

[ 메디채널 김갑성 기자 ] Designation underscores potential of chemically induced, off-the-shelf cell therapy to address high unmet need in Parkinson's disease, following compelling Phase I clinical data CHENGDU, China, Jan. 19, 2026 -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, today announced that its lead product, NouvNeu001, has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA) for the treatment of Parkinson
- 김갑성 기자
- 2026-01-19 21:00
Ageing, smoking, oral bacteria and genetic mutations linked…

[ 메디채널 김갑성 기자 ] Duke-NUS and NUHS scientists uncover a complex web of genetic, age-related and microbial factors that increase the risk of stomach cancer. Age-related blood cell mutations may trigger early changes in the stomach lining, offering new insights into how cancer risk builds over time and underscoring the importance of healthy ageing. Findings point to new ways to identify individuals at highest risk of developing stomach cancer, opening opportunities for targeted prevention and precise screening. SINGAPORE, Jan. 19, 2026 -- Scientists at Duke-NUS Medical School and
- 김갑성 기자
- 2026-01-19 20:07
Akeso Announces NMPA Acceptance of Second NDA for Gum…

HONG KONG, Jan. 19, 2026 -- Akeso, Inc. (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatment of active ankylosing spondylitis (AS), has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). There are approximately 4 million AS patients in China, and gumokimab represents a potentially promising new therapeutic option for this disease. Active ankylosing spondylitis (AS) is the second indication for which gumokimab h
- 김갑성 기자
- 2026-01-19 19:24
6Letters Launches "MOJO KING," an Apple Watch-Based iOS A…

SEOUL, South Korea, Jan. 19, 2026 -- Digital healthcare startup 6Letters today announced the official launch of MOJO KING, an iOS application that enables non-invasive monitoring of testosterone-related physiological patterns using Apple Watch data. MOJO KING leverages heart rate variability (HRV)—a standard biometric signal collected by Apple Watch—to analyze changes associated with male hormonal balance. Without requiring blood tests or external sensors, the app allows users to track hormone-related trends seamlessly in everyday life. The current version of MOJO KING a
- 김갑성 기자
- 2026-01-19 18:49
Smartee Denti-Technology Releases 2025 Year-in-Review: 10…

SHANGHAI, Jan. 19, 2026 -- Smartee Denti-Technology today released its 2025 annual review, detailing a pivotal year characterized by the worldwide clinical application of its proprietary mandibular repositioning technology, the inauguration of new European infrastructure, and a strategic partnership with the Straumann Group. The 2025 review highlights Smartee's transition from rapid growth to sustained maturity, underscored by advancements in three key pillars: clinical efficacy, global supply chain capability, and professional education. Clinical Milestone: Applicating Mandibul
- 김갑성 기자
- 2026-01-19 17:46
Sharjah Achieves Historic WHO Age-Friendly Status

SHARJAH, UAE, Jan. 19, 2026 -- The Emirate of Sharjah, UAE, has reached a new global milestone by obtaining "Advanced Affiliate" membership in the World Health Organization's (WHO) Global Network for Age-Friendly Cities and Communities. This makes Sharjah the first Arab city to achieve this prestigious status. This achievement underscores the emirate's deep commitment to enhancing the well-being of its senior residents and fostering an inclusive, supportive environment for all age groups. It aligns with Sharjah's vision of building a cohesive society based on human welfare.&n
- 김갑성 기자
- 2026-01-19 16:00
D3 Bio Receives U.S. FDA Clearance for Two IND Applications, En…

SHANGHAI, Jan. 19, 2026 -- D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications: D3S‑003 — a KRAS G12D inhibitor — enabling the start of a Phase 1 first‑in‑human clinical trial. A Phase 2 combination trial evaluating D3S‑001 (elisrasib), the Company's next‑generation KRAS G12C inhibitor, in combination with D3S‑002, a selective oral ERK1/2 inhibitor. D3S‑003 is an ora
- 김갑성 기자
- 2026-01-19 09:00
Harbour BioMed Acquires Common Stock in Spruce Bioscienc…

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 19, 2026 -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owned subsidiary, it has exercised its warrant to acquire the common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB) ("Spruce"). Following this transaction, Harbour BioMed holds approximately 3.8% of the total outstanding shares of Spruce and approximately 3.1% of the fully diluted shares of Spruce[1
- 김갑성 기자
- 2026-01-19 08:02
WuXi AppTec Receives Double "A" Rating from CDP for Climate Ch…

SHANGHAI, Jan. 19, 2026 -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized on the "A List" for leadership in corporate transparency and performance across both Climate Change and Water Security by CDP (Carbon Disclosure Project). This recognition, which represents CDP's highest rating in each category, underscores WuXi AppTec's achievements in climate change and water resource management and its ongoing commitment to sustainable development. CDP is a global non-pro
- 김갑성 기자
- 2026-01-19 08:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2026-01-31_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 31일 13시 40분